23 May 2013
Keywords: gsk, initiates, ph, iii, hep, promacta, studies
Article | 21 November 2007
UK drug major GlaxoSmithKline says it has begun two parallel Phase III studies designed to evaluate Promacta/ Revolade (eltrombopag) in
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
21 November 2007
22 May 2013
© 2013 thepharmaletter.com